These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28152526)

  • 1. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
    Kim DW; Byer J; Kothari N; Mahipal A; Chang YD; Kim RD
    Oncology; 2017; 92(4):190-196. PubMed ID: 28152526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor inhibition in metastatic anal cancer.
    Rogers JE; Ohinata A; Silva NN; Mehdizadeh A; Eng C
    Anticancer Drugs; 2016 Sep; 27(8):804-8. PubMed ID: 27272412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
    Berlin J; Posey J; Tchekmedyian S; Hu E; Chan D; Malik I; Yang L; Amado RG; Hecht JR
    Clin Colorectal Cancer; 2007 Mar; 6(6):427-32. PubMed ID: 17531105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
    Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
    Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
    Phan LK; Hoff PM
    Dis Colon Rectum; 2007 Mar; 50(3):395-8. PubMed ID: 17252287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
    J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma.
    De Dosso S; Martin V; Zanellato E; Frattini M; Saletti P
    Tumori; 2010; 96(4):627-8. PubMed ID: 20968146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma.
    Valery M; Cervantes B; Smolenschi C; Boilève A; Boige V; Malka D; Hollebecque A; Ducreux M
    Dig Liver Dis; 2023 Mar; 55(3):407-411. PubMed ID: 36088220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
    Khawandanah M; Baxley A; Pant S
    J Oncol Pharm Pract; 2015 Jun; 21(3):232-7. PubMed ID: 24627343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
    Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
    Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
    Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
    Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
    Hasegawa H; Taniguchi H; Mitani S; Masuishi T; Komori A; Narita Y; Kadowaki S; Ura T; Ando M; Yatabe Y; Muro K
    Oncology; 2017; 92(4):205-212. PubMed ID: 28142137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced anal squamous cell carcinoma -- radiotherapy or surgery?
    Smigielski J; Rychter A; Fijuth J; Brocki M
    Chirurgia (Bucur); 2012; 107(5):626-30. PubMed ID: 23116837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients.
    Doci R; Zucali R; La Monica G; Meroni E; Kenda R; Eboli M; Lozza L
    J Clin Oncol; 1996 Dec; 14(12):3121-5. PubMed ID: 8955657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
    Grabenbauer GG; Kessler H; Matzel KE; Sauer R; Hohenberger W; Schneider IH
    Dis Colon Rectum; 2005 Sep; 48(9):1742-51. PubMed ID: 15991058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.